Economic Evaluation of Mepolizumab as Add-on Therapy to Standard Care in Severe Eosinophilic Asthma: A Cost-Effectiveness Analysis in Colombia
Although mepolizumab improves patients' quality of life, it is not considered cost-effective in Colombia under the conditions of this study. The results provide valuable information for policymakers to consider when refining local clinical practice guidelines.
Authors
- Carlos E. Rodríguez‐Martínez (ORCID: https://orcid.org/0000-0003-2560-6693)
- Jefferson Antonio Buendía (ORCID: https://orcid.org/0000-0003-2404-6612)
- Ranniery Acuña‐Cordero (ORCID: https://orcid.org/0000-0001-8944-4027)
Institutions
- Universidad El Bosque (CO)
- Universidad de Antioquia (CO)
- Universidad Nacional de Colombia (CO)
- Military University Nueva Granada (CO)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/jaa.s502216
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16